http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H10501212-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate | 1995-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1998-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H10501212-A |
| titleOfInvention | Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-HT <1D> -alpha agonists |
| abstract | (57) [Summary] The following formula (I) (Wherein Z is an optionally substituted 5-membered heteroaromatic selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole. E represents a chemical bond or a linear or branched alkylene chain having 1 to 4 carbon atoms; Q represents a linear or branched alkylene chain having 1 to 6 carbon atoms which may be substituted at any position by a hydroxyl group; T represents nitrogen or CH; U represents nitrogen or C—R 2 ; V represents oxygen, sulfur or N—R 3 ; -FG represents —CH 2 —N—; —CH 2 —CH— or —CH ＝ C—; R 1 is C 3-6 alkenyl, C 3-6 alkynyl, aryl (C 1-6 ) alkyl or heteroaryl Le (C 1-6) alkyl, these both groups may be substituted; salt of the compound or a compound of R 2 and R 3 independently represent hydrogen or C 1-6 alkyl) Alternatively, the prodrug is a selective agonist of the 5-HT 1 -like receptor, and is a potent agonist of the human 5-HT 1D α receptor subtype, but has a 5-HT 1D α subtype. Has at least a 10-fold selective affinity for the 5-HT 1D α receptor subtype as compared to Accordingly, the compounds of the present invention are useful in the treatment and / or prevention of clinical conditions requiring a subtype-selective agonist of the 5-HT 1D receptor, especially in the treatment and / or prevention of migraine and related disorders, and Fewer side effects, especially adverse cardiovascular side effects, as compared to those related to 5-HT 1D receptor agonists. |
| priorityDate | 1994-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 499.